- Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
- Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
- Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
- Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
- Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
- Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
- Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.62 |
---|---|
High | 2.74 |
Low | 2.50 |
Bid | 2.61 |
Offer | 2.83 |
Previous close | 2.58 |
Average volume | 54.16k |
---|---|
Shares outstanding | 37.58m |
Free float | 34.15m |
P/E (TTM) | -- |
Market cap | 101.85m USD |
EPS (TTM) | -2.13 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼